

<b>SUSPECT ADVERSE REACTION REPORT</b>												

## I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) <b>KKR</b>	1a. COUNTRY <b>UNITED STATES</b>	2. DATE OF BIRTH			2a. AGE <b>30 Years</b>	3. SEX <b>Male</b>	3a. WEIGHT <b>30.00 kg</b>	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION  <input type="checkbox"/> PATIENT DIED <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY <input checked="" type="checkbox"/> LIFE THREATENING
		Day <b>12</b>	Month <b>SEP</b>	Year <b>1990</b>			Day <b>12</b>	Month <b>JAN</b>	Year <b>2016</b>		
7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas) <b>Rash [Rash pruritic]</b> <b>Cerebral Haemorrhage [Cerebral haemorrhage]</b>  Case Description: This serious report from study report from the United States received on 06-SEP-2016 by an investigator describes the occurrence of Cerebral haemorrhage, and Death in a 25 year-old White male subject taking Rxstudy1 as a participant in the following clinical trial protocol: Rx Study 1: Clinical study double blinded for drug and vaccine  The past medical history for the subject included: Hypertension, <div style="text-align: right;">(Continued on Additional Information Page)</div>											

## II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1 ) Cipla US Tablet (P-COUMARIC ACID 100 g) Injection, 100 millimole {Lot # 12345; Exp.Dt. 01-SEP-2016} #2 ) ALP VACCINE (PARACETAMOL 32 DF, HYDROCHLORIC ACID 56 <div style="text-align: right;">(Continued on Additional Information Page)</div>		20. DID REACTION ABATE AFTER STOPPING DRUG?  <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA
15. DAILY DOSE(S) #1 ) 50 mg, bid #2 )	16. ROUTE(S) OF ADMINISTRATION #1 ) Oral #2 ) Unknown	
17. INDICATION(S) FOR USE #1 ) Constipation (Constipation) #2 ) Unknown		21. DID REACTION REAPPEAR AFTER REINTRODUCTION?  <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA
18. THERAPY DATES(from/to) #1 ) JUL-2016 / 15-AUG-2016 #2 ) Unknown		
19. THERAPY DURATION #1 ) Unknown #2 ) Unknown		

## III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)		
From/To Dates	Type of History / Notes	Description
05-AUG-2016 to Ongoing	Current Condition	Hyperaemia (Hyperaemia)
		The patient's currently suffering from "Hperaemia"
01-JAN-2014 to 06-MAY-2014	Historical Condition	Abdominal pain (Abdominal pain)
		Patient suffered from "Abdominal Pain" in the past

## IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER Rxlogix James M Potter 500 College Rd East, Suite 203 Princeton, New Jersey 08540 UNITED STATES Phone: 223 910 1072 Extn: 1 609		26. REMARKS Medically Confirmed: Yes
	24b. MFR CONTROL NO. <b>16US001978</b>	25b. NAME AND ADDRESS OF REPORTER Mr Chris Dept: Pathology, Pathlab REF: QA-89 21/6 Author Road Trenton, New Jersey 1278 UNITED STATES
24c. DATE RECEIVED BY MANUFACTURER <b>06-SEP-2016</b>	24d. REPORT SOURCE <input type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input checked="" type="checkbox"/> HEALTH PROFESSIONAL <input checked="" type="checkbox"/> OTHER: Spontaneous	
DATE OF THIS REPORT <b>02-JUL-2018</b>	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

02-Jul-2018 06:03